November 17, 2015
The Prix Galien Canada 2015 award for Research was shared by Drs John KELTON and Theodore WARKENTI (McMaster University) for their extensive studies on the mechanism, manifestation, diagnosis and possible treatments of heparin-induced thrombocytopenia.
The award for Best Innovative Product was bestowed to Boehinger Ingelheim (Canada) Ltd for afatinib (Giotrif®). Giotrif® is a second generation tyrosine kinase inhibitor that differs from first-generation tyrosine kinase inhibitors by irreversibly inhibiting HER2 and HER4 receptors in addition to the tyrosine kinase activity of EGFR, and, in non-small cell lung cancer clinical trials, demonstrating prolonged progression-free survival, improved quality of life, and an overall survival benefit compared with standard chemotherapy in patients harbouring an EGF Del19 mutation.
For further information please contact Ms. Sylvie JACQUES, Sylviejacquesprixgalien@gmail.com
